Insider Selling: Medpace Holdings Inc (NASDAQ:MEDP) CEO Sells $3,204,568.17 in Stock
Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 29,019 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $110.43, for a total value of $3,204,568.17. Following the completion of the transaction, the chief executive officer now owns 616,643 shares of the company’s stock, valued at approximately $68,095,886.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
MEDP opened at $119.35 on Friday. Medpace Holdings Inc has a fifty-two week low of $58.72 and a fifty-two week high of $144.49. The business has a 50-day moving average of $96.91 and a 200-day moving average of $88.75. The company has a debt-to-equity ratio of 0.16, a current ratio of 0.94 and a quick ratio of 0.89. The company has a market capitalization of $4.23 billion, a PE ratio of 42.47 and a beta of 1.22.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, July 27th. The company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.40 by $0.28. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The company had revenue of $205.00 million during the quarter, compared to the consensus estimate of $181.17 million. During the same period last year, the business earned $0.81 EPS. The business’s quarterly revenue was down 4.3% on a year-over-year basis. On average, equities research analysts expect that Medpace Holdings Inc will post 2.36 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the company. Robert W. Baird raised Medpace from an “underperform” rating to a “neutral” rating and set a $83.00 price objective for the company in a research note on Monday, June 8th. BidaskClub raised Medpace from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Wolfe Research downgraded Medpace from an “outperform” rating to a “peer perform” rating and set a $91.00 price objective for the company. in a research note on Wednesday, May 13th. Zacks Investment Research raised Medpace from a “hold” rating to a “strong-buy” rating and set a $137.00 price objective for the company in a research note on Saturday. Finally, Credit Suisse Group increased their price objective on Medpace from $92.00 to $114.00 and gave the stock an “outperform” rating in a research note on Tuesday. Four analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. Medpace presently has an average rating of “Buy” and an average target price of $103.29.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: What is the G-20?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.